Vyome Seals Strategic Pact With Impetis Biosciences, Unlocking a ~$57 Billion Market Horizon
Vyome Partners With Impetis, a TATA Enterprise, to In‑License Next‑Generation JAK Inhibitors, Unlocking a ~$57B Global Market Opportunity Vyome has signed a landmark agreement with Impetis Biosciences, a TATA Enterprise, to in‑license two highly...
Recent Comments